恩替卡韦
药代动力学
最大值
背景(考古学)
肝硬化
医学
药理学
肝纤维化
胃肠病学
化学
内科学
慢性肝炎
免疫学
生物
病毒
古生物学
拉米夫定
作者
Tao Yang,Tian-Hui Zheng,Qiang Zhao,Wei Liu,Shuping Li,Yanyan Tao,Changhong Wang,Chenghai Liu
标识
DOI:10.1080/13880209.2019.1687527
摘要
CONTEXT: Fuzheng Huayu recipe (FZHY) combined with entecavir (ETV) is used to treat the cirrhosis caused by chronic hepatitis B (CHB) infection. OBJECTIVE: To investigate the effect of FZHY on ETV pharmacokinetics under different conditions. MATERIALS AND METHODS: A model of liver fibrosis was created by intraperitoneal injection of dimethylnitrosamine (DMN; 10 μg/kg) for 4 weeks in Wistar rats. Ultra-high-performance liquid chromatography–tandem mass spectrometry was used to determine the blood concentration of ETV. Pharmacokinetic characteristics of ETV (0.9 mg/kg) were investigated after co-administration with FZHY (0.55 g/kg) at certain time intervals in normal and model rats. RESULTS: The analytical method for ETV was validated at 0.5–50 μg/L with a correlation coefficient = 0.9996, lower limit of quantitation of 0.5 μg/L and mean accuracy of 104.18 ± 9.46%. Compared with the ETV-N group, the pharmacokinetic parameters of the EF-2 group did not change significantly, but that of the EF-0 group decreased in C(max) to 27.38 μg/L, in AUC(0–)(t) from 323.84 to 236.67 μg/h/L, and a delay in T(max) from 0.75 to 6.00 h; that of the EF-0 group presented a decrease in C(max) of 61.92%, delay in t(1/2) of 2.45 h and delay in T(max) of 2.92 h. The t(1/2e) and V(d)/F of ETV were increased significantly to 8.01 h and 24.38 L/kg in the ETV-M group. CONCLUSIONS: The effects of FZHY on ETV pharmacokinetics were diminished with an increase of interval time. The best time to administer both drugs is >2 h apart.
科研通智能强力驱动
Strongly Powered by AbleSci AI